OPTIMIZE-1
Issuance to bring Alligator closer to the market
Alligator Bioscience ended 2024 by announcing a sharper focus on the lead candidate mitazalimab. The company is now focusing on...
Alligator CEO: "We are on track to secure a partnership"
Soren Bregenholt
Powerful data drives Alligator Bioscience forward
Alligator Bioscience has had a successful...
“Unprecedented” Phase II data for Alligator in pancreatic cancer
Alligator Bioscience continues to present compelling Phase II data...
Alligator Biosciences CSO presents CD40 portfolio at conference
Alligator Biosciences' CD40 agonist mitazalimab has recently shown promise...
FDA approves Alligator's Phase II study
Alligator BioScience continues to make progress with its...
Alligator's CMO hosts in-depth webinar on Mitazalimab
At the beginning of the year, Alligator BioScience...
Alligator Bioscience presents positive interim data
Alligator Bioscience's CEO Søren Bregenholt visited BioStock's studio...
Alligator Bioscience's Q3 is out – comments from the CEO
Swedish Alligator Bioscience recently published its report for...
Alligator Bioscience is ready for an exciting news flow
A lot is going on at Alligator Bioscience....
Alligator Bioscience's CEO looks ahead
Recently, Lund-based Alligator Bioscience delivered its report for...
Allegro Investment Fund about the ownership in Alligator Bioscience
Recently, Allegro Investment Fund exceeded the 25 percent...